Overview

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies

Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.
Phase:
Phase 2
Details
Lead Sponsor:
Praxis Precision Medicines
Treatments:
Pramoxine